RAPHAEL PHARMACEUTICL INC (RAPH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RAPH SEC filings page.
This page shows RAPHAEL PHARMACEUTICL INC (RAPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
By FY2025, the reported balance sheet had shifted from positive equity to liabilities exceeding assets, while operations still consumed cash.
The current ratio fell from 1.8x in FY2023 to near zero in FY2025 while equity turned negative, indicating short-term obligations became disconnected from near-term asset coverage. That combination reflects a balance-sheet contraction: liabilities expanded as the asset base shrank, rather than the business simply carrying obligations against a growing asset base.
FY2025 operating cash flow was
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
RAPHAEL PHARMACEUTICL INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
RAPHAEL PHARMACEUTICL INC earned $0.01 per diluted share (EPS) in Q2 2026. This represents a decrease of 50.0% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
RAPHAEL PHARMACEUTICL INC held $1K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
RAPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | N/A | N/A | N/A | $141K+487.5% | $72K-81.0% | N/A | $162K-68.2% |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | $353K+110.1% | N/A | $157K-28.3% |
| Operating Income | N/A | N/A | N/A | N/A | N/A | -$425K+22.3% | N/A | N/A |
| Interest Expense | N/A | $3K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$429K+22.0% | N/A | N/A |
| EPS (Basic) | $0.01-50.0% | $0.01-50.0% | $0.020.0% | $0.010.0% | $0.02+100.0% | $0.02-33.3% | $0.02+200.0% | $0.01-75.0% |
| EPS (Diluted) | $0.01-50.0% | $0.01-50.0% | $0.020.0% | $0.010.0% | $0.02+100.0% | $0.02-33.3% | $0.02+200.0% | $0.01-75.0% |
| Diluted Shares (Avg) | 20M+2.8% | 20M+2.8% | N/A | 20M+4.9% | 20M+5.1% | 20M+5.4% | N/A | 19M+13.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
RAPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7K-76.7% | $3K-96.8% | $53K+96.3% | $7K-86.3% | $30K-76.6% | $93K-73.7% | $27K-88.7% | $51K-87.3% |
| Current Assets | $6K-78.6% | $1K-98.9% | $51K+104.0% | $5K-89.8% | $28K-77.8% | $91K-74.0% | $25K-89.5% | $49K-87.8% |
| Cash & Equivalents | $1K-95.0% | $1K-98.0% | $45K+136.8% | $3K-92.5% | $20K-83.3% | $50K-82.6% | $19K-91.7% | $40K-86.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.9M+75.5% | $1.7M+101.3% | $1.5M+93.2% | $1.3M+90.6% | $1.1M+157.9% | $827K+81.4% | $769K+482.6% | $667K+39.5% |
| Current Liabilities | $1.9M+75.5% | $1.7M+101.3% | $1.5M+93.2% | $1.3M+90.6% | $1.1M+157.9% | $827K+81.4% | $769K+482.6% | $667K+39.5% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$1.9M-79.9% | -$1.7M-126.4% | -$1.4M-93.1% | -$1.3M-105.2% | -$1.0M-261.4% | -$734K-612.6% | -$742K-793.5% | -$616K-721.3% |
| Retained Earnings | -$10.6M-10.2% | -$10.4M-11.6% | -$10.2M-14.4% | -$9.9M-17.3% | -$9.6M-18.9% | -$9.3M-18.5% | -$8.9M-20.6% | -$8.4M-13.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RAPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0+100.0% | N/A | $46K+174.2% | -$17K+78.8% | -$30K+86.2% | -$209K-21.5% | -$62K+29.5% | -$80K+84.0% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | $197K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | -$4K-109.8% | $0 | $0-100.0% | $240K+4.3% | $41K+115.8% | $0-100.0% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
RAPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$1.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| RAPHAEL PHARMACEUTICL INC RAPH | FY2025 | N/A | N/A | N/A | $30.5M | — |
| WEED INC BUDZ | FY2025 | $0 | -$1.4M | N/A | $3.0M | — |
| LFTD PARTNERS INC LIFD | FY2025 | $36.9M | -$24.9M | -67.3% | $1.5M | — |
Where RAPHAEL PHARMACEUTICL INC Ranks
Frequently Asked Questions
What is RAPHAEL PHARMACEUTICL INC's operating cash flow?
RAPHAEL PHARMACEUTICL INC (RAPH) recorded an outflow of $210K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are RAPHAEL PHARMACEUTICL INC's total assets?
RAPHAEL PHARMACEUTICL INC (RAPH) had $53K in total assets as of fiscal year 2025, including both current and long-term assets.
What is RAPHAEL PHARMACEUTICL INC's current ratio?
RAPHAEL PHARMACEUTICL INC (RAPH) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is RAPHAEL PHARMACEUTICL INC's P/E ratio?
RAPHAEL PHARMACEUTICL INC (RAPH) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $30.5M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is RAPHAEL PHARMACEUTICL INC's price-to-sales ratio?
RAPHAEL PHARMACEUTICL INC (RAPH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $30.5M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does RAPHAEL PHARMACEUTICL INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, RAPHAEL PHARMACEUTICL INC (RAPH) held $45K in cash, cash equivalents and investments, and reported an operating cash outflow of $210K over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is RAPHAEL PHARMACEUTICL INC's debt-to-equity ratio negative or not reported?
RAPHAEL PHARMACEUTICL INC (RAPH) has negative shareholder equity of -$1.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.